导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.16% | 3943/4773 |
| 近一周 | -3.24% | 3852/5458 |
| 近一月 | -2.76% | 1687/5421 |
| 近一季 | 0.99% | 775/5205 |
| 近半年 | -4.66% | 2782/4920 |
| 近一年 | -15.65% | 3765/4361 |
| 近两年 | 27.58% | 2429/2954 |
| 近三年 | 8.19% | 1795/2253 |
| 成立以来 | 22.55% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.40% 4649/4961 |
8.82% 2534/5312 |
- - |
- - |
| 2025 | 3.87% 3089/4813 |
-6.45% 3356/3635 |
4.23% 825/4076 |
10.87% 3231/4524 |
-3.93% 3358/4813 |
| 2024 | 25.53% 257/3463 |
-4.68% 1738/2808 |
-8.21% 2190/3014 |
42.93% 35/3129 |
0.38% 1219/3463 |
| 2023 | 4.37% 231/2656 |
3.99% 1075/2280 |
-2.65% 625/2385 |
7.57% 34/2515 |
-4.16% 897/2655 |
| 2022 | -24.53% 1227/2207 |
-17.76% 1258/1919 |
2.01% 1383/2016 |
-15.16% 1228/2113 |
6.03% 398/2208 |
| 2021 | -0.92% 770/1822 |
-13.65% 1160/1255 |
7.75% 669/1330 |
4.76% 322/1466 |
1.66% 846/1822 |
| 2020 | - - |
- - |
- - |
17.90% 95/1164 |
2.09% 1011/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华夏中证全指证券公司ETF联接C VS. 长安沪深300非周期A(740101) |